TVTX
Travere Therapeutics Inc
53.40$
-4.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 27.6% | 58.9% | 63.3% | 62.6% | 69.9% | 70.9% | 67.6% | 75.0% | 72.3% | 78.2% | 70.1% | 72.3% | |
| 13.4% | 7.4% | 7.8% | 19.1% | 14.5% | 10.3% | 14.0% | 21.3% | 9.2% | 7.4% | 9.9% | 15.4% | |
| 20.5% | 44.8% | 48.7% | 57.8% | 66.5% | 65.9% | 59.5% | 71.2% | 66.9% | 71.9% | 62.4% | 53.3% | |
| 5.9% | 11.6% | 12.4% | 2.7% | 2.0% | 3.0% | 5.4% | 2.0% | 2.5% | 2.7% | 4.6% | 13.2% | |
| 0.6% | 0.5% | 0.5% | 1.0% | 0.8% | 1.0% | 1.3% | 0.9% | 0.7% | 1.2% | 1.0% | 1.0% | |
| – | – | – | 0.6% | 0.4% | 0.5% | 5.8% | 1.4% | 1.3% | – | – | – | |
| 0.7% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | – | |
| 69.6% | 31.5% | 34.7% | 35.5% | 26.3% | 26.0% | 25.2% | 19.0% | 14.3% | 13.1% | 17.4% | 18.7% | |
| 127.5% | 41.5% | 41.4% | 43.7% | 55.1% | 63.4% | 65.2% | 61.1% | 93.6% | 74.5% | 90.1% | 81.0% | |
| 79.4% | 16.7% | 15.9% | 16.5% | 14.8% | 15.8% | 15.3% | 16.0% | 21.1% | 22.6% | 33.8% | 26.4% | |
| 29.9% | – | – | – | 3.2% | 0.4% | 0.1% | 0.5% | 0.7% | 0.6% | 12.5% | 1.0% | |
| 5.3% | 1.5% | 1.4% | 3.6% | 1.0% | 4.4% | 2.0% | 1.9% | 2.6% | 5.3% | 4.0% | 4.1% | |
| – | – | – | 8.7% | 27.5% | 33.9% | 35.5% | 29.2% | 55.8% | 47.8% | 52.2% | 51.5% | |
| -27.5% | 58.5% | 58.6% | 56.3% | 44.9% | 36.6% | 34.8% | 38.9% | 6.4% | 25.5% | 9.9% | 19.0% | |
| -132.3% | -12.7% | -21.5% | -34.1% | -38.1% | -68.9% | -96.5% | -98.6% | -150.8% | -142.7% | -243.6% | -243.3% | |
| 18.5% | 7.3% | 7.3% | 7.5% | 5.7% | 7.0% | 7.8% | 7.7% | 9.5% | 9.4% | 13.3% | 14.7% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.